The effects of methylene blue on renal scarring due to pyelonephritis in rats.
The aim of this study was to evaluate the efficiency of methylene blue (MB) in preventing renal scar formation after the induction of pyelonephritis (PNP) in a rat model with delayed antimicrobial therapy. An inoculum of the K-12 strain of Escherichia coli was injected into both kidneys. Control groups received isotonic saline instead of bacterial solution. Four equal groups were then formed: the PNP group was untreated and the PNP ciprofloxacin (CIP) treated group was treated only with CIP intraperitoneally (i.p.) starting on the third day following bacterial inoculation. In the PNP (MB)-treated group, MB was given i.p., and in the PNP MB + CIP-treated group, MB + CIP were administered i.p.. In the sixth week following bacterial inoculation, all rats were sacrificed, and both kidneys of the rats in all groups were examined biochemically and histopathologically for renal scarring. Renal scar was significant in the groups treated with MB alone or MB + CIP combination compared with untreated or antibiotic only groups. Delayed treatment with antibiotics had no effect on scarring. These results suggest that the addition of MB to the delayed antibiotic therapy might be beneficial in preventing PNP-induced oxidative renal tissue damage.
Aksu
Burhan
B
Department of Pediatric Surgery, Faculty of Medicine, Trakya University, Edirne, Turkey. burhanfeyza@yahoo.com
Inan
Mustafa
M
Kanter
Mehmet
M
Oz Puyan
Fulya
F
Uzun
Hafize
H
Durmus-Altun
Gulay
G
Gurcan
Saban
S
Aydin
Seval
S
Ayvaz
Suleyman
S
Pul
Mehmet
M
D000818:Animals; D000890:Anti-Infective Agents / Q000627:therapeutic use; D000892:Anti-Infective Agents, Urinary / Q000494:pharmacology / Q000627:therapeutic use*; D002921:Cicatrix / Q000517:prevention & control*; D002939:Ciprofloxacin / Q000627:therapeutic use; D004195:Disease Models, Animal; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004927:Escherichia coli Infections / Q000188:drug therapy / Q000473:pathology; D048168:Escherichia coli K12 / Q000472:pathogenicity; D005260:Female; D007274:Injections, Intraperitoneal; D007668:Kidney / Q000187:drug effects* / Q000382:microbiology / Q000473:pathology*; D008751:Methylene Blue / Q000494:pharmacology / Q000627:therapeutic use*; D011704:Pyelonephritis / Q000188:drug therapy* / Q000209:etiology; D051381:Rats; D017207:Rats, Sprague-Dawley
D000890:Anti-Infective Agents; D000892:Anti-Infective Agents, Urinary; D002939:Ciprofloxacin; D008751:Methylene Blue